231 related articles for article (PubMed ID: 34871373)
21. Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia.
Maude SL; Laetsch TW; Buechner J; Rives S; Boyer M; Bittencourt H; Bader P; Verneris MR; Stefanski HE; Myers GD; Qayed M; De Moerloose B; Hiramatsu H; Schlis K; Davis KL; Martin PL; Nemecek ER; Yanik GA; Peters C; Baruchel A; Boissel N; Mechinaud F; Balduzzi A; Krueger J; June CH; Levine BL; Wood P; Taran T; Leung M; Mueller KT; Zhang Y; Sen K; Lebwohl D; Pulsipher MA; Grupp SA
N Engl J Med; 2018 Feb; 378(5):439-448. PubMed ID: 29385370
[TBL] [Abstract][Full Text] [Related]
22. Anti-CD19 chimeric antigen receptor-modified T-cell therapy bridging to allogeneic hematopoietic stem cell transplantation for relapsed/refractory B-cell acute lymphoblastic leukemia: An open-label pragmatic clinical trial.
Jiang H; Li C; Yin P; Guo T; Liu L; Xia L; Wu Y; Zhou F; Ai L; Shi W; Lu X; Wang H; Tang L; Wei Q; Deng J; Jin R; Xiong W; Dong J; Mei H; Hu Y
Am J Hematol; 2019 Oct; 94(10):1113-1122. PubMed ID: 31321805
[TBL] [Abstract][Full Text] [Related]
23. CAR T-cell therapy is effective for CD19-dim B-lymphoblastic leukemia but is impacted by prior blinatumomab therapy.
Pillai V; Muralidharan K; Meng W; Bagashev A; Oldridge DA; Rosenthal J; Van Arnam J; Melenhorst JJ; Mohan D; DiNofia AM; Luo M; Cherian S; Fromm JR; Wertheim G; Thomas-Tikhonenko A; Paessler M; June CH; Luning Prak ET; Bhoj VG; Grupp SA; Maude SL; Rheingold SR
Blood Adv; 2019 Nov; 3(22):3539-3549. PubMed ID: 31738832
[TBL] [Abstract][Full Text] [Related]
24. Anti-CD19 chimeric antigen receptors T cells for the treatment of relapsed or refractory E2A-PBX1 positive acute lymphoblastic leukemia: report of three cases.
Zhang J; Yang F; Qiu HY; Wu Q; Kong DQ; Zhou J; Han Y; Wu DP
Leuk Lymphoma; 2019 Jun; 60(6):1454-1461. PubMed ID: 30714847
[TBL] [Abstract][Full Text] [Related]
25. Potent preclinical activity of FLT3-directed chimeric antigen receptor T-cell immunotherapy against
Niswander LM; Graff ZT; Chien CD; Chukinas JA; Meadows CA; Leach LC; Loftus JP; Kohler ME; Tasian SK; Fry TJ
Haematologica; 2023 Feb; 108(2):457-471. PubMed ID: 35950535
[TBL] [Abstract][Full Text] [Related]
26. Impact of poverty and neighborhood opportunity on outcomes for children treated with CD19-directed CAR T-cell therapy.
Newman H; Li Y; Liu H; Myers RM; Tam V; DiNofia A; Wray L; Rheingold SR; Callahan C; White C; Baniewicz D; Winestone LE; Kadauke S; Diorio C; June CH; Getz KD; Aplenc R; Teachey DT; Maude SL; Grupp SA; Bona K; Leahy AB
Blood; 2023 Feb; 141(6):609-619. PubMed ID: 36351239
[TBL] [Abstract][Full Text] [Related]
27. Preinfusion factors impacting relapse immunophenotype following CD19 CAR T cells.
Lamble AJ; Myers RM; Taraseviciute A; John S; Yates B; Steinberg SM; Sheppard J; Kovach AE; Wood B; Borowitz MJ; Stetler-Stevenson M; Yuan CM; Pillai V; Foley T; Chung P; Chen L; Lee DW; Annesley C; DiNofia A; Grupp SA; Verneris MR; Gore L; Laetsch TW; Bhojwani D; Brown PA; Pulsipher MA; Rheingold SR; Gardner RA; Shah NN
Blood Adv; 2023 Feb; 7(4):575-585. PubMed ID: 35482927
[TBL] [Abstract][Full Text] [Related]
28. Determinants of outcomes and advances in CD19-directed chimeric antigen receptor therapy for B-cell acute lymphoblastic leukemia.
Gupta S; Kohorst M; Alkhateeb HB
Eur J Haematol; 2024 Jan; 112(1):51-63. PubMed ID: 38105391
[TBL] [Abstract][Full Text] [Related]
29. Integrating CAR T-Cell Therapy and Transplantation: Comparisons of Safety and Long-Term Efficacy of Allogeneic Hematopoietic Stem Cell Transplantation After CAR T-Cell or Chemotherapy-Based Complete Remission in B-Cell Acute Lymphoblastic Leukemia.
Zhao YL; Liu DY; Sun RJ; Zhang JP; Zhou JR; Wei ZJ; Xiong M; Cao XY; Lu Y; Yang JF; Zhang X; Lu DP; Lu P
Front Immunol; 2021; 12():605766. PubMed ID: 34025637
[TBL] [Abstract][Full Text] [Related]
30. Anti-CD19 chimeric antigen receptor T-cell therapy in acute lymphocytic leukaemia: a systematic review and meta-analysis.
Anagnostou T; Riaz IB; Hashmi SK; Murad MH; Kenderian SS
Lancet Haematol; 2020 Nov; 7(11):e816-e826. PubMed ID: 33091355
[TBL] [Abstract][Full Text] [Related]
31. Does lineage plasticity enable escape from CAR-T cell therapy? Lessons from MLL-r leukemia.
Liao W; Kohler ME; Fry T; Ernst P
Exp Hematol; 2021 Aug; 100():1-11. PubMed ID: 34298117
[TBL] [Abstract][Full Text] [Related]
32. Tisagenlecleucel-T for the treatment of acute lymphocytic leukemia.
Thomas X; Paubelle E
Expert Opin Biol Ther; 2018 Nov; 18(11):1095-1106. PubMed ID: 30296188
[TBL] [Abstract][Full Text] [Related]
33. Unmanipulated haploidentical hematopoietic stem cell transplantation is an excellent option for children and young adult relapsed/refractory Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia after CAR-T-cell therapy.
Hu GH; Zhao XY; Zuo YX; Chang YJ; Suo P; Wu J; Jia YP; Lu AD; Li YC; Wang Y; Jiao SC; Zhang LJ; Kong J; Yan CH; Xu LP; Zhang XH; Liu KY; Cheng YF; Wang Y; Zhang LP; Huang XJ
Leukemia; 2021 Nov; 35(11):3092-3100. PubMed ID: 33824464
[TBL] [Abstract][Full Text] [Related]
34. Which one is better for refractory/relapsed acute B-cell lymphoblastic leukemia: Single-target (CD19) or dual-target (tandem or sequential CD19/CD22) CAR T-cell therapy?
Liu S; Zhang X; Dai H; Cui W; Yin J; Li Z; Yang X; Yang C; Xue S; Qiu H; Miao M; Chen S; Jin Z; Fu C; Li C; Sun A; Han Y; Wang Y; Yu L; Wu D; Cui Q; Tang X
Blood Cancer J; 2023 Apr; 13(1):60. PubMed ID: 37095120
[TBL] [Abstract][Full Text] [Related]
35. Sequential CD19 and CD22 chimeric antigen receptor T-cell therapy for childhood refractory or relapsed B-cell acute lymphocytic leukaemia: a single-arm, phase 2 study.
Pan J; Tang K; Luo Y; Seery S; Tan Y; Deng B; Liu F; Xu X; Ling Z; Song W; Xu J; Duan J; Wang Z; Li C; Wang K; Zhang Y; Yu X; Zheng Q; Zhao L; Zhang J; Chang AH; Feng X
Lancet Oncol; 2023 Nov; 24(11):1229-1241. PubMed ID: 37863088
[TBL] [Abstract][Full Text] [Related]
36. Tisagenlecleucel in Acute Lymphoblastic Leukemia: A Review of the Literature and Practical Considerations.
Halford Z; Anderson MK; Bennett LL; Moody J
Ann Pharmacother; 2021 Apr; 55(4):466-479. PubMed ID: 32762363
[TBL] [Abstract][Full Text] [Related]
37. Impact of
Shouval R; Alarcon Tomas A; Fein JA; Flynn JR; Markovits E; Mayer S; Olaide Afuye A; Alperovich A; Anagnostou T; Besser MJ; Batlevi CL; Dahi PB; Devlin SM; Fingrut WB; Giralt SA; Lin RJ; Markel G; Salles G; Sauter CS; Scordo M; Shah GL; Shah N; Scherz-Shouval R; van den Brink M; Perales MA; Palomba ML
J Clin Oncol; 2022 Feb; 40(4):369-381. PubMed ID: 34860572
[TBL] [Abstract][Full Text] [Related]
38. CAR T-cells in acute lymphoblastic leukemia: Current results.
Dourthe ME; Baruchel A
Bull Cancer; 2021 Oct; 108(10S):S40-S54. PubMed ID: 34920807
[TBL] [Abstract][Full Text] [Related]
39. Combination of CD19 and CD22 CAR-T cell therapy in relapsed B-cell acute lymphoblastic leukemia after allogeneic transplantation.
Liu S; Deng B; Yin Z; Lin Y; An L; Liu D; Pan J; Yu X; Chen B; Wu T; Chang AH; Tong C
Am J Hematol; 2021 Jun; 96(6):671-679. PubMed ID: 33725422
[TBL] [Abstract][Full Text] [Related]
40. INSPIRED Symposium Part 4A: Access to CAR T Cell Therapy in Unique Populations with B Cell Acute Lymphoblastic Leukemia.
Winestone LE; Bhojwani D; Ghorashian S; Muffly L; Leahy AB; Chao K; Steineck A; Rössig C; Lamble A; Maude SL; Myers R; Rheingold SR
Transplant Cell Ther; 2024 Jan; 30(1):56-70. PubMed ID: 37821078
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]